"目录号: HY-14151
GPCR/G ProteinNeuronal Signaling-
Prucalopride (R093877)是高亲和性5-HT4受体激动剂，对5-HT4a/4b的pKi分别为8.6/8.1，比对其它受体的亲和性高150倍。
5-HT Receptor
相关产品
Clozapine N-oxide-Chlorpromazine hydrochloride-Pimavanserin-Brexpiprazole-Lorcaserin Hydrochloride-Scopolamine hydrobromide-Cariprazine hydrochloride-Harmine-Lu AE58054 Hydrochloride-TG6-10-1-Perphenazine-Aripiprazole-Ferulic acid sodium-Olanzapine-Sertindole-
生物活性
Description
Prucalopride (R093877) is a drug acting as a selective, high affinity 5-HT4 receptor agonist(pKi=8.6/8.1 for 5-HT4a/4b); >150-fold higher affinity for 5-HT4 receptors than for other receptors.IC50 value: 8.6/8.1 for 5-HT4a/4b(pKi)Target: 5-HT4 receptorPrucalopride is a novel enterokinetic compound and is the first representative of the benzofuran class. Receptor binding data have demonstrated prucalopride's high affinity to both investigated 5-HT(4) receptor isoforms, with mean pK(i) estimates of 8.60 and 8.10 for the human 5-HT(4a) and 5-HT(4b) receptor, respectively. From the 50 other binding assays investigated in this study only the human D(4) receptor (pK(i) 5.63), the mouse 5-HT(3) receptor (pK(i) 5.41) and the human sigma(1) (pK(i) 5.43) have shown measurable affinity, resulting in at least 290-fold selectivity for the 5-HT(4) receptor [1].
Clinical Trial
NCT01674192
Movetis
Constipation
July 1997
Phase 1
NCT01116206
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Constipation
May 2010
Phase 3
NCT01670669
Movetis
Constipation
November 1998
Phase 1
NCT00488215
Movetis
Constipation
January 2000
Phase 1
NCT01692132
Janssen Pharmaceutica
Chronic Constipation
February 2013
Phase 4
NCT02004652
Jinling Hospital, China
Postoperative Ileus
November 2013
Phase 2
NCT00903747
Movetis
Constipation
January 2009
Phase 1
NCT01117051
Shire
Non-cancer Pain-Opioid Induced Constipation
May 2010
Phase 3
NCT01674166
Movetis
Constipation
November 1998
Phase 1
NCT02510976
Universitaire Ziekenhuizen Leuven
Gastroparesis
November 2011
Phase 4
NCT00576511
Movetis
Chronic Constipation
December 1994
Phase 2
NCT02781493
Shandong University-Binzhou People's Hospital-Tai'an People's Hospital-Linyi People's Hospital
Prucalopride Plus Polyethylene Glycol in Bowel Preparation for Colonoscopyp
June 2016
Phase 4
NCT01864915
Queen's University-Hotel Dieu Hospital-Janssen Inc.
Bowel Cleansing-Colon Capsule Completion Times
June 2013
Phase 3
NCT02047045
Guang'anmen Hospital of China Academy of Chinese Medical Sciences-Ministry of Science and Technology of the People´s Republic of China
Constipation
April 2014
NCT01807000
Shire
Healthy
March 2013
Phase 1
NCT00596596
Movetis
Constipation
September 1996
Phase 2
NCT00488137
Movetis
Constipation
March 1998
Phase 3
NCT00631813
Movetis
Constipation
November 1995
Phase 2
NCT02806206
University of British Columbia
Gastrointestinal Hemorrhage-Crohn Disease-Celiac Disease-Intestinal Diseases-Inflammatory Bowel Diseases
July 2016
Phase 4
NCT00598338
Movetis
Constipation
April 1999
Phase 3
NCT01424228
Shire
Constipation
June 2011
Phase 4
NCT02947269
University of Auckland, New Zealand
Postoperative Ileus-Colorectal Surgery-Postoperative Complications
January 2017
Phase 3
NCT00483886
Movetis
Constipation
April 1998
Phase 3
NCT01251822
Norgine
Constipation
November 2010
Phase 3
NCT00617513
Movetis
Constipation
March 1995
Phase 2
NCT00575614
Movetis
Constipation
April 1997
Phase 2
NCT01147926
Shire
Male Subjects With Chronic Constipation
September 2010
Phase 3
NCT01707667
Shire
Chronic Constipation
January 2013
Phase 4
NCT01036893
Movetis-FOCUS GmbH
Healthy Volunteers
December 2009
Phase 1
NCT00987844
Movetis
Chronic Constipation
July 1998
Phase 3
NCT02228616
Xian-Janssen Pharmaceutical Ltd.
Constipation
October 2014
Phase 4
NCT02031081
University of Calgary-Janssen Inc.
Gastroparesis-Diabetes Mellitus
March 2014
Phase 2-Phase 3
NCT01330381
Shire-PRA Health Sciences
Functional Constipation
April 2011
Phase 3
NCT01134185
Movetis
Hepatic Impairment
May 2010
Phase 1
NCT00487422
Movetis
Constipation
October 1998
Phase 3
NCT00485940
Movetis
Constipation
March 1998
Phase 3
NCT01070615
Movetis
Chronic Constipation
June 1998
Phase 3
NCT00627692
Movetis
Constipation
February 1999
Phase 2
NCT00793429
Movetis
Healthy
Phase 1
NCT01869751
Universitaire Ziekenhuizen Leuven
Constipation
May 2013
NCT00577018
Movetis
Constipation
August 1998
Phase 3
NCT01655095
Queen's University-Hotel Dieu Hospital (Gastrointestinal Diseases Research Unit)
Quality of Bowel Preparation for the Colon Capsule-Colon Capsule Completion Rates-Colon Capsule Polyp Detection
July 2012
Phase 3
NCT01902537
Janssen Korea, Ltd., Korea
Constipation
August 2012
Phase 4
NCT02425774
Katholieke Universiteit Leuven-Universitaire Ziekenhuizen Leuven
Postoperative Ileus
July 2014
Phase 4
NCT01870674
Yuhan Corporation
Healthy
August 2013
Phase 1
NCT02538367
Yuhan Corporation
Functional Constipation
August 2015
Phase 1-Phase 2
View MoreCollapse
References
[1].Briejer MR, et al. The in vitro pharmacological profile of prucalopride, a novel enterokinetic compound. Eur J Pharmacol. 2001 Jun 29;423(1):71-83.
[2].Emmanuel AV, et al. Randomised clinical trial: the efficacy of prucalopride in patients with chronic intestinal pseudo-obstruction--a double-blind, placebo-controlled, cross-over, multiple n = 1 study. Aliment Pharmacol Ther. 2012 Jan;35(1):48-55.
[3].Bouras EP, et al. Selective stimulation of colonic transit by the benzofuran 5HT4 agonist, prucalopride, in healthy humans. Gut. 1999 May;44(5):682-6.